Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

Neurology

Volumn 67, Issue 7, 2006, Pages 1242-1249

  Kappos, L ^a   Polman, C H ^b   Freedman, M S ^c   Edan, G ^d   Hartung, H P ^e   Miller, D H ^f   Montalban, X ^g   Barkhof, F ^b   Bauer, L ^h   Jakobs, P ^h   Pohl, C ^h,i   Sandbrink, R ^h  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF OTTAWA   (Canada)

^d Clinique Neurologique   (France)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h BAYER PHARMA AG   (Germany)

ⁱ UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INTERFERON BETA SERINE; LIVER ENZYME; PLACEBO;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMYELINATING DISEASE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; INJECTION SITE REACTION; KAPLAN MEIER METHOD; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARALLEL DESIGN; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SCORING SYSTEM; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ADULT; CANADA; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; INTERFERON-BETA; ISRAEL; MALE; MULTIPLE SCLEROSIS; PLACEBO EFFECT; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 33749661011     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000237641.33768.8d     Document Type: Article

References (29)

1. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
2. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-1582.
3. Achiron A, Kishner I, Sarova-Pinhas I, et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol 2004;61:1515-1520.
4. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
5. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
6. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-846.
7. Dalton CM, Brex PA, Miszkiel KA, et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002;52:47-53.
8. Tintore M, Rovira A, Rio J, et al. New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 2003;60:27-30.
9. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
10. Uitdehaag BM, Kappos L, Bauer L, et al. Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization. Mult Scler 2005;11:227-231.
11. Good Clinical Practice principles according to the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use E6. Available at: http://www.emea.eu.int/pdfs/ human/ich/013595en.pdf
12. Cella DF, Dineen K, Arnason B, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996;47:129-139.
13. Moore F, Wolfson C, Alexandrov L, et al. Do general and multiple sclerosis-specific quality of life instruments differ? Can J Neurol Sci 2004;31:64-71.
14. Pungor E Jr., Files JG, Gabe JD, et al. A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. J Interferon Cytokine Res 1998;18:1025-1030.
15. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120 (Pt 11):2059-2069.
16. Barkhof F, Rocca M, Francis G, et al. Validation of diagnostic MRI criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol 2003;53:718-724.
17. Stokes ME, Davis CS, Koch G. Categorical data analysis using the SAS System. Second ed. 2000: 174-179.
18. Frohman EM, Goodin DS, Calabresi PA, et al. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003;61:602-611.
19. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993;43:662-667.
20. Miller DH, Molyneux PD, Barker GJ, et al. Effect of interferon-beta1b on MRI outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis. Ann Neurol 1999;46:850-859.
21. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
22. Kuhlmann T, Lingfeld G, Bitsch A, et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002;125:2202-2212.
23. Ebers GC. Prognostic factors for multiple sclerosis: the importance of natural history studies. J Neurol 2005;252(Suppl 3):iii15-iii20.
24. Once Weekly Interferon for MS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology 1999;53:679-686.
25. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
26. O'Connor P. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS. Clin Ther 2003;25:2865-2874.
27. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double- blind, placebo-controlled trial. Neurology 1993;43:655-661.
28. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-1497.
29. Houari Y, Brochet B, Grau G, Epicure Study Group. Reduction of injection site reactions of MS patients newly started on Betaferon® therapy with the Betaject® and Betaject® Light autoinjectors. Mult Scler 2004;10(Suppl 2):252. Abstract.